Celldex Therapeutics stock gains as analysts target USD 56.42

Celldex Therapeutics (ISIN US15117B1035) opened at USD 41.62 on September 21, 2026, after a prior close of USD 38.24, and later traded at USD 38.3170 on Nasdaq. The move came with volume of 28,369 shares and put the clinical-stage biopharmaceutical company under renewed scrutiny.

Stock opens above prior close

The opening price was USD 3.38 above the previous close, although the later quoted price of USD 38.3170 was below the opening level. The same September 21, 2026 market report placed Celldex's market capitalization at USD 2.99 billion and its 50-day and 200-day moving averages at USD 39.13 and USD 34.75, respectively, according to MarketBeat.

Quarterly loss beats estimate

Celldex reported a quarterly loss of USD 0.94 per share for the quarter reported on August 6, 2026, beating the consensus loss estimate of USD 1.06 per share by USD 0.12. Revenue was USD 0.02 million, compared with a consensus estimate of USD 0.73 million, according to MarketBeat.

The earnings comparison is mixed: the USD 0.12 per-share beat was favorable against expectations, while reported revenue represented only a small fraction of the USD 0.73 million consensus estimate. Analysts were reported to expect a full-year loss of USD 4.17 per share for the current fiscal year, according to MarketBeat.

Analyst targets remain divided

Analyst views span a wide range. Guggenheim raised its price target from USD 90.00 to USD 100.00 on July 20, 2026, while Canaccord Genuity Group cut its target from USD 62.00 to USD 60.00 on July 22, 2026; both reports retained buy ratings, as reported by MarketBeat. The reported consensus rating was Moderate Buy with a consensus price target of USD 56.42, based on the September 21, 2026 overview.

Celldex is developing antibody-based therapies in immunology, inflammation and oncology. Its lead investigational product, barzolvolimab, targets the KIT receptor and is being studied in chronic spontaneous urticaria and prurigo nodularis, according to MarketBeat. For investors, the key contrast is between a USD 0.12 quarterly EPS beat and the company's continuing expected full-year loss of USD 4.17 per share.

CLDX trades below moving averages

Celldex shares traded at USD 38.3170 on Nasdaq on September 21, 2026. That level was below the reported 50-day average of USD 39.13 but above the 200-day average of USD 34.75, providing a dated technical reference without changing the company's clinical-stage risk profile.

More news and analyses on Celldex Therapeutics stock